A Phase 3, Multicenter, Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic) (Protocol Number A1281198)

The purpose of this research study is to compare the effects of the study drug, Ziprasidone (Geodon®), with a placebo to find out which is better for treating manic episode in children with Bipolar I Disorder.

Eligibility

Males and females 10 to 17 years of age with a diagnosis of bipolar I (current or most recent episode manic) will be recruited to participate.

Reimbursement

Yes

Investigator

PI: David Kaye, MD

Contact Information

Name: Sevie Kandefer, MS
Phone: 716-898-4038
Email: sk293@buffalo.edu